Vertex’s executive chairman: Here’s how we got our drug-trial success rate over 70% when the industry’s is 10% to 20%

What happened
Vertex Pharmaceuticals increased its drug trial success rate to over 70% by narrowing its focus to diseases with well-validated biological targets. The company moved away from spreading resources across many research projects and instead concentrated on areas where the likelihood of success was higher. This approach was adopted after previous efforts resulted in only one major product, which was soon surpassed by a competitor. The change in strategy led to the development of several new medicines, including treatments for cystic fibrosis and a gene-editing therapy for sickle cell disease.
Key details
- Vertex's R&D success rate exceeded 83% in Phase II proof of concept across six diseases.
- The industry average for drug trial success is between 10% and 20%.
- Vertex developed five medicines for cystic fibrosis that benefit 95% of patients.
- The company partnered with CRISPR Therapeutics to create the first FDA-approved gene-editing therapy for severe sickle cell disease and transfusion-dependent beta-thalassemia.
Why it matters
Pharmaceutical companies, researchers, and patients are affected by this shift. Companies that focus on selecting the right biological targets may see higher success rates and more efficient use of R&D budgets. Patients benefit from the faster development of effective treatments, and the industry faces new benchmarks for what is possible in drug development success rates.
